bonds. 5 Basically, two kinds of strategies have been developed and widely used for the efficient activation of C(sp 3 )-H bonds:
(a) the strong coordinated bidentate auxiliaries first introduced by Daugulis in 2005, 6, 7 which have inspired the discovery of various bidentate auxiliaries; 8 and (b) the weakly coordinating N-arylamide (CONHAr or CONHOMe) directing groups promoted by external ligands, which were first developed by Yu. 9 In particular, these strategies have found wide applications in the functionalization of naturally occurring α-amino acids (AAs), one of the most abundant biomass-derived chemicals, providing powerful and straightforward methods for the synthesis of unnatural α-AAs. 5a,b,e-g,9-11 It can be expected that the subtle difference of α-substitutions between α-amino acids and α-hydroxy acids might lead to dramatic inconsistence in reactivity due to the following reasons: (a) the N-phthaloyl group that has been widely used in C-H functionalization of α-AAs is more likely to facilitate the desired cyclopalladation via the Thorpe-Ingold effect; 14c,15 while the α-oxygen atom on lactic acid would probably have an adverse effect for the desired transformation, largely because of the tendency to trap the palladium catalyst by competitive coordination.
16 (b) The α-hydroxyl group is known to be unstable under the catalytic system, and is susceptible to β-oxygen elimination to give the corresponding α,β-unsaturated amides after cyclopalladation. Therefore, the reaction conditions have to be carefully tuned to establish a new catalytic system to address these challenges. We first tested the feasibility of the arylation protocol for an alanine derivative using AgBF 4 as the additive. 14f However, the arylation of 1a with aryl iodide 2a only resulted in the elimination of MeOH, probably due to the strong Lewis acidity of AgBF 4 . Therefore, we turned our attention to the screening of various inorganic bases as additives; however, no satisfactory result was obtained (Table 1 , entries 1-3). To maintain the high reactivity and suppress the side reaction of elimination, we reexamined other silver salts with weak Lewis acidity. After extensive screening, we found that the use of AgF afforded the desired product in 65% yield (entry 8). Further investigation of different solvents indicated that polar solvents, such as t-AmylOH, MeOH and DMF, were more suitable to this transformation (entries 9-12).
To our delight, simply increasing the loading of AgF to 3 equivalents could significantly improve the yield (entry 13, 81%). Interestingly, no diarylation product has been observed in all the cases. Under the optimized conditions for the arylation of lactic acid-derived amide 1a, we next examined the scope of aryl iodides (Scheme 1). A variety of aryl iodides were found to be compatible with this protocol and afforded the desired arylated products in good yields. Different functional groups, including alkyl (3b-3d, 3h and 3r), alkoxy (3e-3g, 3t and 3w), fluoro (3i), chloro (3j), bromo (3k), acetyl (3l), nitro (3m), trifluoromethyl (3o), methoxycarbonyl (3p), and hydroxyl (3x) groups, were well tolerated under the reaction conditions. When strong electron-deficient 4-iodobenzonitrile was used as the arylation reagent, the modification of the standard reaction conditions (DMF and Ag 2 O instead of t AmylOH and AgF) could give the desired product 3n in 49% yield. Steric hindrance adjacent to the iodide had a tremendous impact on the reactivity. For example, 2-methyliodobenzene completely shuts down the reaction, and even a less bulky methoxyl group at the ortho-position only gave a moderate yield (3g). Arylation could also proceed smoothly with disubstituted aryl iodides and the desired products were obtained in good yields (3q-3u), which would make this process synthetically attractive. It is worth noting that the arylated product 3r could be converted to the biologically important Danshensu, 2b simply by the removal of the AQ auxiliary and protecting group. Additionally, the heterocyclic coupling partners, such as 2-iodothiophene (2w) and 3-iodoindole (2x), were also compatible with this protocol, giving the desired products 3w and 3x in moderate yields (60% and 59%, respectively).
Additionally, the arylation protocol was also compatible with more complicated coupling partners. The coupling of 1a with glucose-derived aryl iodide (2y) under the standard conditions of arylation afforded the corresponding product 3y in 67% yield (Scheme 2A), which suggested the further synthetic potentials in late-stage modification of complex molecules. The reaction could also be scaled up to 5 mmol giving a synthetically useful yield (Scheme 2B). Further the AQ auxiliary could be easily removed in good yield under mild conditions.
11e As shown in Scheme 2C, the protection of the secondary amide of 3a with Boc 2 O, followed by treatment of the resulting tertiary amide with LiOH/H 2 O 2 , gave the corresponding α-methoxy carboxylic acid 4a in 76% yield. The BocNHQ 4b could be recovered in quantitative yield. LY519818 (4c) and tesaglitazar (4d) have been recognized as potential agonists against peroxisome proliferator-activated receptors (PPARs) for the treatment of type II diabetes.
3 To demonstrate the practical potential of our protocols, the synthesis of these compounds was conducted with the Pd-catalyzed arylation of lactic acid as the key step. As demonstrated in Scheme 2D, starting from substrates 1a and 1b, LY519818 (4c) and tesaglitazar (4d) were obtained in 54% and 37% overall yield, respectively.
In conclusion, we have developed a palladium-catalyzed AQ-directed arylation of lactic acid derivatives for the synthesis of chiral β-aryl-α-hydroxy acids. Despite the intensive study on the arylation of fatty acids and α-amino acids, the reaction here provides a practical alternative to chiral β-aryl-AHAs. A wide range of aryl and heteroaryl iodides bearing various functional groups underwent the arylation successfully. The synthetic importance of these novel protocols were further demonstrated by the synthesis of two biologically important AHAs, LY519818 and tesaglitazar, potential agonists against peroxisome proliferator-activated receptors (PPARs) for the treatment of type II diabetes.
